Retargeting the management of hypercholesterolemia – focus on evolocumab
Alessandro Colletti,1 Giuseppe Derosa,2 Arrigo FG Cicero1 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, 2Department of Internal Medicine and Therapeutics, University of Pavia and Policlinico San Matteo Foundation, Pavia, Italy Abstract: Hypercholesterolemia is one o...
Main Authors: | Colletti A, Derosa G, Cicero AFG |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-09-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/retargeting-the-management-of-hypercholesterolemia-ndash-focus-on-evol-peer-reviewed-article-TCRM |
Similar Items
-
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01) -
Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
by: Henry CA, et al.
Published: (2016-04-01) -
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
by: Dixon DL, et al.
Published: (2017-07-01) -
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
by: Kosmas CE, et al.
Published: (2018-10-01) -
Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01)